Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities

Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis. We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension. In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4, 5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-7720770-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compounds that potently inhibit ROCK enzymatic activity. GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, respectively. GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases. In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-α. Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in preconstricted rat aorta with an IC50 of 39 and 35 nM, respectively. Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. At doses of 1, 3, and 30 mg/kg, both compounds induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg. In addition, administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats. SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.

[1]  K. Dobashi,et al.  Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects. , 2004, International immunopharmacology.

[2]  J. Hieble,et al.  Expression and functional role of Rho‐kinase in rat urinary bladder smooth muscle , 2003, British journal of pharmacology.

[3]  S. Khandekar,et al.  Expression, purification, and characterization of an enzymatically active truncated human rho-kinase I (ROCK I) domain expressed in Sf-9 insect cells. , 2006, Protein and peptide letters.

[4]  Dennis Lee,et al.  Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges , 2005, Expert opinion on therapeutic targets.

[5]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[6]  W. Steers,et al.  RhoA-mediated Ca2+ Sensitization in Erectile Function* , 2002, The Journal of Biological Chemistry.

[7]  Dexter L. Lee,et al.  Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. , 2004, Hypertension.

[8]  N. Suttorp,et al.  Reduction of tumor necrosis factor-alpha (TNF-α) related nuclear factor-kappaB (NF-κB) translocation but not inhibitor kappa-B (Iκ-B)-degradation by Rho protein inhibition in human endothelial cells , 2002 .

[9]  D. Hartshorne,et al.  Activation of RhoA and Inhibition of Myosin Phosphatase as Important Components in Hypertension in Vascular Smooth Muscle , 2003, Circulation research.

[10]  A. Takeshita,et al.  Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in Humans , 2001, Hypertension.

[11]  K. Kaibuchi,et al.  Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.

[12]  A. Dorrance,et al.  Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. , 2004, American journal of hypertension.

[13]  N. Suttorp,et al.  Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. , 2002, Biochemical pharmacology.

[14]  Y. Pinto,et al.  Lessons from rat models of hypertension: from Goldblatt to genetic engineering. , 1998, Cardiovascular research.

[15]  K. Takeda,et al.  Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells , 2001, Hypertension.

[16]  D. Brooks,et al.  Inhibition of Gene Markers of Fibrosis with a Novel Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase in Puromycin-Induced Nephritis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[17]  Y. Kaziro,et al.  G Protein βγ Subunits Induce Stress Fiber Formation and Focal Adhesion Assembly in a Rho-dependent Manner in HeLa Cells* , 2000, The Journal of Biological Chemistry.

[18]  A. Tedgui,et al.  Rho-Associated Protein Kinase Contributes to Early Atherosclerotic Lesion Formation in Mice , 2003, Circulation research.

[19]  A. Takeshita,et al.  Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[21]  K. Dobashi,et al.  Comparison of effects of Y-27632 and Isoproterenol on release of cytokines from human peripheral T cells. , 2003, International immunopharmacology.

[22]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[23]  Y. Yoshikawa,et al.  Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. , 2003, Journal of molecular and cellular cardiology.

[24]  K. Fujisawa,et al.  The small GTP‐binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. , 1996, The EMBO journal.

[25]  S. Narumiya,et al.  Targeted Disruption of the Mouse Rho-Associated Kinase 2 Gene Results in Intrauterine Growth Retardation and Fetal Death , 2003, Molecular and Cellular Biology.

[26]  D. Behm,et al.  p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension , 2003, Journal of Pharmacology and Experimental Therapeutics.

[27]  T. Yamamoto,et al.  Rho‐associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. , 1996, The EMBO journal.

[28]  X. Q. Chen,et al.  The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton , 1996, Molecular and cellular biology.

[29]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[30]  T. Lüscher,et al.  Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.

[31]  Y. Kaziro,et al.  G protein betagamma subunits induce stress fiber formation and focal adhesion assembly in a Rho-dependent manner in HeLa cells. , 2000, The Journal of biological chemistry.

[32]  K. Kaibuchi,et al.  RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[33]  H. Shimokawa.  Rho-kinase as a Novel Therapeutic Target in Treatment of Cardiovascular Diseases , 2002, Journal of cardiovascular pharmacology.

[34]  David G. Behm,et al.  Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist , 2002, British journal of pharmacology.

[35]  Hiroko Oshima,et al.  ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles , 2005, The Journal of cell biology.

[36]  Anne J. Ridley,et al.  ROCKs: multifunctional kinases in cell behaviour , 2003, Nature Reviews Molecular Cell Biology.

[37]  伊藤 浩司.  Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system : Possible involvement in neural mechanisms of hypertension , 2003 .

[38]  J. Galmiche,et al.  Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. , 2003, Gastroenterology.

[39]  J. Liao,et al.  ROCKs as therapeutic targets in cardiovascular diseases , 2005, Expert review of cardiovascular therapy.

[40]  K. Kaibuchi,et al.  Regulation and functions of Rho-associated kinase. , 2000, Experimental cell research.

[41]  W. Bao,et al.  Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. , 2004, Cardiovascular research.